The peptide's effects appear context-dependent
3,4 Published results demonstrate the effectiveness of Omadas behavior change approach, with an analysis finding members in Omadas Enhanced GLP-1 Care Track achieved 28% greater weight loss on average at 4 months compared to those receiving Omadas standard care
Semaglutide inhibits glucagon secretion and stimulates insulin release, which lowers blood glucose levels in people with type 2 diabetes
Last reviewed: June 25, 2026 Last updated: June 25, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
The most frequent issues reported from the phase 3 studies are nausea (19%), fatigue (6%), skin darkening (4%), dizziness (4%), and the development of moles (4%)
Not intended for diagnosis or treatment of any medical condition